Path to real revenue.... I thought this would be a good reminder in contrast to the negative predictions of our chart analyst traders.. It's proven to be a useful tool in changing sentiment of inexperienced penny stock investors to move stock price. I've already expressed my opinion and caution in valuing chart analysis and predictions for penny stocks in earlier post.
Comment on AEMD 9/24/14 news by allpennystock.com.
"Regarding today’s news, Aethlon announced an agreement with Qualtran, LLC that would expand human clinical studies of Hemopurifier therapy to include individuals infected with dengue virus. Qualtran is the contract research organization that originated and managed the previous clinical trials of the Hemopurifier at various sites in India. Further, Qualtran has established a collaborative relationship with India’s National Institute of Virology, resulting in research demonstrating the Hemopurifier’s ability to capture dengue virus. Moving forward, Qualtran has agreed to establish multiple treatment sites and recruit thought leaders from the dengue field to establish consensus treatment protocols in advance of the 2015 dengue outbreak season.
Aethlon intends to incorporate data from the proposed dengue treatment study into a Humanitarian Use Device (HUD) submission. A HUD program provides an alternative FDA pathway for getting market approval for medical devices that may help people with rare diseases or conditions, specifically those affecting less than 4,000 people in the U.S. each year. Efficacy studies are not feasible in the continental U.S., as dengue rarely occurs here, but it is a serious problem in Latin America, Puerto Rico, Southeast Asia and the Pacific Islands."
While I was at first very disappointed when JJ backed-off of pursuits in India two years ago. Strategically it was not good timing. Now that we are well established and further along with our FDA US studies and with our recent Ebola exposure, I think JJ decided it's time to pick up where he left off in India and Asia. Dengue season is this fall and keep in mind we already have a relationship with India's gov. and their NIV and export license has already been FDA approved. Manufacturing logistics should already be well along because we need it completed for the DARPA DLT requirements. Plus it may help that our best US medical centers have established or are seeking relationships with India's health care system....examples are Duke University at Medicity and Qualtran list Cleveland Clinic and Mayo Clinic as Partners. In Asia countries and the Pan America countries (Chicunguna) it's a lot easier to get export and import approvals and being mostly practitioner driven health care, easier to offer HP treatment.
I hope this helps,
Bill
Market Data 
Markets 
AI
